We have used the polymerase chain reaction to amplify the entire coding region of canine factor IX from a hemophilia B animal. When the sequence was compared to that which codes for normal canine factor IX, a single missense mutation was identified. This mutation (G --A at nucleotide 1477) results in the substitution of glutamic acid for glycine-379 in the catalytic domain of the molecule. The mutation creates a new restriction site that allowed confirmation of the abnormal sequence in both hemophilic and carrier animals. Amino acid 379 in canine factor IX corresponds to position 381 in human factor IX, a location at which no human mutations have been described. Moreover, it occurs at one of the few amino acids that have been rigorously conserved among the trypsin-like serine proteases throughout evolution. The mutation responsible for canine hemophilia B results in a complete lack of circulating factor IX in the affected animals. As it is unusual for a missense mutation to result in a complete absence of protein product, structural modeling of the mutant and normal proteins was pursued. These studies suggest that the observed mutation would have major adverse effects on the tertiary structure of the aberrant factor IX molecule. The elucidation of this mutation sheds light on structure-function relationships in factor IX and should facilitate future experiments directed toward gene therapy of this disease.
ABSTRACT
We have used the polymerase chain reaction to amplify the entire coding region of canine factor IX from a hemophilia B animal. When the sequence was compared to that which codes for normal canine factor IX, a single missense mutation was identified. This mutation (G --A at nucleotide 1477) results in the substitution of glutamic acid for glycine-379 in the catalytic domain of the molecule. The mutation creates a new restriction site that allowed confirmation of the abnormal sequence in both hemophilic and carrier animals. Amino acid 379 in canine factor IX corresponds to position 381 in human factor IX, a location at which no human mutations have been described. Moreover, it occurs at one of the few amino acids that have been rigorously conserved among the trypsin-like serine proteases throughout evolution. The mutation responsible for canine hemophilia B results in a complete lack of circulating factor IX in the affected animals. As it is unusual for a missense mutation to result in a complete absence of protein product, structural modeling of the mutant and normal proteins was pursued. These studies suggest that the observed mutation would have major adverse effects on the tertiary structure of the aberrant factor IX molecule. The elucidation of this mutation sheds light on structure-function relationships in factor IX and should facilitate future experiments directed toward gene therapy of this disease.
Factor IX is a 56-kDa plasma glycoprotein that is required for blood coagulation (1) . Factor IX circulates as a zymogen; to become active in coagulation, factor IX must undergo limited proteolytic cleavage by factor XIa or factor VIIa-tissue factor. This proteolytic step cleaves two peptide bonds to generate a short amino acid segment termed the activation peptide and unblocks the active site of the enzyme. This activated form, designated factor IXa, in the presence of its cofactor factor Villa and calcium and phospholipids, cleaves factor X to generate factor Xa, the next step in the coagulation cascade. Factor IX belongs to the seine protease superfamily, a class of enzymes that includes trypsins as well as coagulation and complement proteins, among others (2). These enzymes arose early in evolution and are present in organisms from bacteria to man. Through evolution, they have acquired a variety of specialized functions. The serine proteases of the coagulation cascade possess, in addition to a trypsin-like active site, domains that are thought to confer cofactor and receptor specificity.
Analysis of the genomic organization of the human factor IX gene has provided insight into the structure of the protein.
The gene contains eight exons that can be correlated in a rough way with the functional domains of the protein (3). Exon I codes for the signal sequence, exon II codes for the y-carboxyglutamic acid-rich region, exon III codes for the short aromatic acid stack, exons IV and V code for the epidermal growth factor-like domains, exon VI codes for the activation peptide, and exons VII and VIII code for the catalytic domain and the long 3' untranslated region, respectively. Although genomic structure has been reported only for human factor IX, a cDNA sequence is available for canine factor IX (4), and the amino acid sequence is available for bovine factor IX (5). Comparison of sequences among these species reveals >90% conservation of residues in the ycarboxyglutamic acid-rich region and in the heavy chain and a much lower degree of conservation in the activation peptide.
An absence of functional factor IX results in the sex-linked bleeding disorder hemophilia B. Current treatment of hemophilia B requires the infusion of factor IX-rich plasma concentrates during bleeding episodes. Such treatments must be repeated with each episode of bleeding and carry a risk of contamination by infectious agents. The possibility of treating hemophilia B by gene therapy has been proposed; one approach would involve the introduction of a gene encoding factor IX into the somatic cells of an affected individual. Hemophilia B is an attractive target for gene transfer therapy since neither precise regulation of factor IX levels nor tissue-specific expression is required. A further advantage is the existence of an animal model of hemophilia B (6, 7), a potentially valuable resource in trials of gene therapy (8, 9) . To maximize the utility of canine hemophilia B in such studies, it is desirable to know the causative mutation at the molecular level. In this report we describe the isolation and characterization of the cDNA encoding mutant (hemophilic) canine factor IX. The molecular defect responsible for this strain of canine hemophilia B is a missense mutation in a highly conserved residue of the catalytic domain; it results in a complete lack of detectable protein in the circulation of the affected animals. (11) . Total RNA was isolated from frozen (-700C) dog liver using the guanidinium thiocyanate method of Chirgwin et al. (12) . For Southern (13) and Northern (14) blot analysis, a 32P-labeled human factor TX cDNA was used as a probe (15) .
MATERIALS AND METHODS
Reverse Transcription and DNA Amplification. Synthesis of single-stranded complementary DNA from a template oftotal hepatic RNA was carried out by the method of Gubler and Hoffman (16) with several modifications (4). (dT)12_18 was used as a primer for reverse transcription.
Amplification offactor IX reverse transcripts was achieved by subjecting the single-stranded cDNA to the polymerase chain reaction (PCR) (17) . Priming oligonucleotides were based on the sequence of normal canine factor IX (4). A typical experiment involved reverse transcription of 50 ,ug of total hepatic RNA. The reaction mixture was extracted with phenol and chloroform and precipitated overnight in ethanol at -20'C. Twelve percent of the total was centrifuged, washed, and dissolved in 10 Al of lOx PCR buffer (670 mM Tris-HCl, pH 8.8/67 mM EDTA/100 mM 2-mercaptoethanol/166 mM (NH4)2SO4/67 mM MgCI2). The final volume of the reaction was 100 1.d and contained 10% (vol/vol) dimethyl sulfoxide, 1.5 mM deoxynucleoside triphosphates, oligonucleotide primers (each at a concentration of 0.5 ,uM), and 2.5 units of thermostable polymerase (Cetus). Amplification was carried out manually with an initial denaturing step at 94°C for 7 min. Annealing was at 55°C for 3 min, extension at 70°C for 4 min, and denaturation at 94°C for 3 min. The reactions were subjected to 35 cycles of amplification after which agarose electrophoresis and electroelution were used to isolate the appropriate fragments. When genomic DNA was used as starting material, a 133-base-pair-(bp) fragment containing the mutation was amplified. Priming oligonucleotides were constructed based on the normal canine sequence (4) (GenBank accession no. M21757). Dde I (New England BioLabs) was used according to manufacturer's recommendations.
Subcloning and DNA Sequencing. The termini of the amplified DNA were phosphorylated with T4 nucleotide kinase (New England BioLabs) and the fragments were subcloned into dephosphorylated M13 vectors. Sequencing was by the method of Sanger et al. (18) , and in certain regions oligonucleotides were constructed for use as primers in the sequencing reactions. The entire coding region of factor IX as well as 149 bp of 3' untranslated material were sequenced in both orientations. When discrepancies arose between the normal canine factor IX sequence (4) and that obtained from the hemophilic animal, the area in question was subjected to two additional independent amplifications from newly synthesized cDNA to eliminate the possibility of a polymerase error masquerading as a mutation.
Amino Acid Sequence Alignment and Structural Modeling. Alignment of the primary structure of the protease domain of canine factor IX with those of human factor IX, trypsin, chymotrypsin, elastase, kallikrein, and Streptomyces griseus protease A was based on sequence identity and structural topological equivalence (19) (20) (21) . Modeling of human factor IX has been described (21) and was based primarily upon the known high-resolution structure of bovine pancreatic trypsin (22) . determine whether other animals within the colony had the same mutation. A 133-bp fragment surrounding the mutation was amplified by PCR from genomic DNA and digested with Dde I. The results, shown in Fig. 3 , demonstrate that the four normal animals tested do not contain the mutation and that the carrier and hemophilic animals do (demonstrated by the presence of the 79-bp and 54-bp fragments).
RESULTS
Protein Alignment. The catalytic domain of the trypsin-like serine proteases has been highly conserved throughout evolution. Amino acid alignment of the members of this family of proteases demonstrates that certain amino acids have remained invariant from bacteria to humans. Fig. 4 shows the amino acid alignment of the heavy chain of canine factor IX with the corresponding region of several other serine proteases (human factor IX, trypsin, elastase, chymotrypsin, kallikrein, and Streptomyces griseus protease A). As can be seen, the mutation in canine factor IX affects one of these highly conserved amino acids, substituting a negatively charged residue (glutamic acid) for an amino acid that is uncharged and possesses no side chain (glycine).
Structural Modeling. The substitution of a glutamic acid for a glycine within the catalytic domain of canine factor IX would be likely to have profound structural consequences. To investigate this possibility further, a structural model of the mutant protein was constructed. Fig. 5A shows a structural model of the heavy chain of human factor IX. This should be representative of the structure of the canine molecule, since, for the amino acids illustrated, there is complete conservation in identity between human and canine factor IX. Fig. 5B depicts this region after substitution of a glutamic acid for glycine at position 381, the mutation found in the hemophilic canine. This model suggests that substitution of a glutamic acid at position 211 leads to prohibitive spatial conflicts with several residues (Leu-162, Phe-181, His-199, and Tyr-228) and alters the hydrophobic character of this closely packed and internal region of factor IX.
DISCUSSION
The characterization of mutations that give rise to hemophilia B in humans has provided insight into critical functional regions of the factor IX molecule. Since the heavy chains of human and canine factor IX show remarkable identity (4), our description of the mutation responsible for canine hemophilia B provides similar insight into structure-function relationships of the human molecule. There has been no previous report of a human mutation at the site corresponding to the one we report here in canine hemophilia (position 379 in canine and position 381 in human factor IX). This mutation occurs at a residue that has remained invariant in serine proteases from bacteria to humans. The profound effect of the mutation on factor IX levels suggests that the glycine at position 379 (position 211 in the chymotrypsinogen numbering system) plays a critical role in the integrity of the trypsin-like serine proteases in general.
Hemophilia B has been classified traditionally as either cross-reacting-material-positive in which antigenically detectable protein is present or cross-reactive-materialnegative in which protein is not detected. The hemophilic canines were found to have undetectable levels of factor IX by two independent assays. This represents an unusual situation among factor IX mutations, since in those characterized to date, missense mutations have always resulted in detectable levels of factor IX (23) . Indeed, it is unusual in general for a missense mutation to result in an absence of IMl. 16 20 4 . Amino acid sequence alignment of the protease domain of canine factor IX (CFIX) with human factor IX (HFIX), bovine trypsin (TRYP), porcine elastase (ELAS), bovine chymotrypsin (CHYM), porcine kallikrein (KALL), and Streptomyces griseus protease A (SGPA). Conserved amino acids are boxed. The position of the mutation in canine hemophilia is denoted by an asterisk. The numbering system is that of chymotrypsinogen A, and deletions are indicated by dashes. detectable translated protein. For example, >400 missense mutations have been described in the globins (representing 25% of all possible mutations) (24) and only 2 of these (25, 26) result in stable mRNA but a lack of detectable protein in the circulation. Similarly, severe a1-antitrypsin deficiency has been found to result from deletions or premature termination codons 'but has thus far not' been attributed to a missense mutation. Among >80 missense mutations analyzed in a1-antitrypsin deficiency, all result in the production of appreciable levels of protein (27) .
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Northern blot analysis (Fig. 1) indicated that factor IX mRNA is present in similar steady-state levels in the normal and' hemophilic dogs, suggesting that failure of expression occurs at a posttranscriptionaIl level. Several explanations could account for the absence ofdetectable protein, including decreased translation, impaired secretion, or production of an unstable polypeptide. Structural modeling of factor IX suggests' that folding of the mutant protein is likely to be severely disrupted and thus offers a possible explanation for the absence of factor IX. The tertiary structure of factor IX has not been determined using x-ray diffraction techniques; however, firm structural data exist for a number of trypsinlike serine proteases, and there is good reason to believe that the degree of sequence identity that exists between the clotting proteins and other members of this enzyme family translates into a high degree of structural homology (20, 21, 28) . Examination of the factor IX model predicts that the presence of a glutamic acid side chain at position 211 would result in significant steric hindrance that in turn would cause improper folding ofthe molecule and structural instability. As Fig. 5 shows, replacement of glycine with a glutamic acid residue results in prohibitively close contacts with Leu-162, Phe-181, His-199, and Tyr-228, all of which are tightly packed together in this central and internal region of the enzyme. Furthermore, the charged character of the glutamic acid side chain is incompatible with the hydrophobic nature of these surrounding residues.
The fact that other hemophilic animals demonstrate the same mutation does not eliminate the possibility that the mutation we describe is a tightly linked polymorphism; however, it does demonstrate unequivocally that the mutation segregates with the hemophilic phenotype. This, coupled with the structural modeling data and the absence of any other mutations, strongly suggests that the glycine --glutamic acid change is indeed the causative mutation.
The canine model of hemophilia B represents a valuable resource in trials of gene therapy, and the characterization of the defect will facilitate use of the animal model. The lack of antigenically detectable factor IX is an advantage for gene therapy trials, since even low levels of expression of a foreign factor IX gene should be readily distinguished from baseline.
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